Lab marker
ApoB
Apolipoprotein B · ApoB-100
The single most informative blood marker for cardiovascular risk — counts every atherogenic particle, not just the cholesterol they carry.
What it measures
ApoB is a structural protein found on every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a), chylomicron remnants). Because each particle carries exactly one ApoB, the test counts particles directly. LDL-C, by contrast, measures the cholesterol cargo — two people with the same LDL-C can have very different particle counts, and particle count predicts events more accurately than cholesterol content.
Reference context
4 guideline sources
Laboratory reference ranges typically report 'normal' up to ~120–130 mg/dL based on population distribution. Population-typical is not the same as optimal — most epidemiological evidence supports lower-is-better down to ~40 mg/dL for atherosclerotic risk.
Population context — consult guideline targets below
Mechanism
Why moving this marker matters
Atherosclerosis is initiated by ApoB-containing particles entering and being retained in the arterial wall. Particle number is the proximal driver of plaque progression; cholesterol cargo is a downstream consequence. Mendelian randomisation across multiple cohorts has shown that lifelong lower ApoB causally reduces coronary disease risk.
Guideline targets
What major guidelines recommend
ESC 2021 (general population)
<100 mg/dL
ESC 2021 (high CV risk)
<80 mg/dL
ESC 2021 (very-high CV risk)
<65 mg/dL
AACE 2017 (high risk)
<90 mg/dL
How to measure
The test, where to get it, when to repeat
Method
Standard blood draw, non-fasting acceptable. Most modern labs report in mg/dL.
Where
Through your GP, or directly via private lab providers in most markets (Medichecks, Thriva, Quest, Labcorp, Synlab).
Typical cost
€10–30 private; usually covered when ordered by a physician for cardiovascular risk assessment.
Fasting
Not required
When to test
ESC 2021 Prevention
40+Measure at least once in all adults; repeat every 5 years if low-risk, more frequently if elevated.
AACE/ACE 2017
Use ApoB alongside or instead of LDL-C for risk stratification, particularly with metabolic syndrome or hypertriglyceridaemia.
NLA 2014
Reasonable secondary target after LDL-C in high-risk patients.
Where to test
Independent labs offering this test
Healicus refers you to independent laboratories. You order from the lab; they take the sample, run it, and return your result on their own platform. Healicus never sees your value.
Randox Health
UK · EU · INTLClinic-based premium panels — wider biomarker breadth than home-test brands.
Visit Randox Health
Synlab
DE · EU · INTLEurope-wide medical lab network — referrals via partner GPs and direct-to-consumer programmes where offered.
Visit Synlab
Medichecks
UKUKAS-accredited home blood-test panels with GP-equivalent biomarker coverage.
Visit Medichecks
Thriva
UKApp-first subscription home testing, capillary draw, clinician-reviewed reports.
Visit Thriva
Healicus is not the provider. Your contract for the service is with whoever you choose. Links labelled Sponsored are paid affiliate relationships; unlabelled links are editorial reference only. See our disclosure for the full policy.
Context
Reading the numbers
Laboratory reference ranges typically report 'normal' up to ~120–130 mg/dL based on population distribution. Population-typical is not the same as optimal — most epidemiological evidence supports lower-is-better down to ~40 mg/dL for atherosclerotic risk.
Caveats
Assay variation is small (<5%). Levels are stable across the day and largely unaffected by recent meals, unlike triglycerides.
Practices
What's been shown to influence this marker
PREDIMED-style Mediterranean dietary pattern reduces ApoB in RCTs; effect size moderate (~5–15% reduction).
High-dose EPA (icosapent ethyl) lowers triglyceride-rich ApoB; lower-dose fish-oil supplementation has smaller effects.
Mediterranean dietary pattern
Habit·Olive oil, fish, nuts, legumes, plants. The most-studied diet for cardiovascular and cognitive longevity.
Why
The Mediterranean pattern — heavy on plants, olive oil, fish, nuts, legumes; moderate fish and dairy; light on red meat — has the strongest evidence base of any specific diet for long-term cardiovascular and cognitive outcomes. PREDIMED, the largest trial, showed ~30% reduction in major cardiovascular events vs. low-fat control.
Slot in your day
How to do it
How
Olive oil as the primary fat. Plants at every meal. Fish 2–3× per week. Nuts daily (small handful). Red meat once a week or less. Wine optional, with food.
Sticking with it
Stock the kitchen for one week's pattern. Decisions live in the shopping list, not at mealtime.
Markers this may influence
Evidence
Omega-3 (EPA + DHA)
Supplement·Cardiovascular and cognitive benefits at 1–2g combined EPA+DHA. Skip if you eat 2+ servings of fatty fish weekly.
Why
EPA and DHA are long-chain omega-3 fatty acids primarily from fatty fish. They reduce triglycerides, support cell membrane function, and are concentrated in brain tissue. Supplementation is most useful for people who don't eat fatty fish regularly. Algae-derived versions exist for vegetarians.
How it works
Incorporated into cell membranes; competes with arachidonic acid in eicosanoid synthesis, shifting inflammatory signalling toward resolution.
Expected onset · ~12 weeks for steady-state membrane uptake
How to take
Dosage
1–2g combined EPA+DHA daily (check the label — total fish oil weight is misleading).
Timing
With a meal containing fat
On the label
Look for combined EPA+DHA per serving on the label, not just 'fish oil 1000mg'. Third-party tested for purity (IFOS, USP).
Ideal for
Anyone who eats fatty fish less than twice per week.
Safety
Markers this may influence
Evidence
Where to get it
As an Amazon Associate, Healicus earns from qualifying purchases.
See also
Related markers
Take to your physician
Worth discussing
- Whether ApoB or LDL-C is more useful given your risk profile.
- If ApoB and LDL-C disagree (common with metabolic syndrome), which to target.
- Whether your absolute ApoB warrants discussion of lifestyle, lifestyle plus pharmacotherapy, or pharmacotherapy directly.
Sources
Cited literature
- [1]ESC 2021 Guidelines on cardiovascular disease prevention in clinical practice(2021)
- [2]AACE/ACE 2017 dyslipidaemia management guidelines(2017)
- [3]National Lipid Association recommendations for patient-centered management of dyslipidaemia(2014)
- [4]Estruch et al., PREDIMED trial — Primary prevention of cardiovascular disease with a Mediterranean diet(2018)
- [5]Bhatt et al., REDUCE-IT — Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridaemia(2019)
- [6]Ference et al., Mendelian randomisation — variants in ApoB causally lower LDL-C and reduce coronary disease risk(2017)
- [7]Sniderman et al., A meta-analysis of low-density lipoprotein cholesterol, non-HDL cholesterol, and ApoB as markers of cardiovascular risk(2011)
Edited by Carl Pöhl, MD · Healicus editorial
Last reviewed May 2026
Keep reading